These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 21349414

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors.
    Massironi S, Conte D, Sciola V, Spampatti MP, Ciafardini C, Valenti L, Rossi RE, Peracchi M.
    Am J Gastroenterol; 2010 Sep; 105(9):2072-8. PubMed ID: 20372113
    [Abstract] [Full Text] [Related]

  • 4. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
    Belli SH, Oneto A, Aranda C, O'Connor JM, Domenichini E, Roca E, Méndez G, Bestani MC, Parma P, Giacomi N, Marmissolle F.
    Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
    [Abstract] [Full Text] [Related]

  • 5. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R, Libutti SK, Saif MW.
    JOP; 2013 Mar 10; 14(2):155-7. PubMed ID: 23474561
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.
    Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, De Braud F, Delle Fave G, Dogliotti L, degli Uberti EC, Italian CromaNet Working Group.
    Endocr Relat Cancer; 2007 Jun 10; 14(2):473-82. PubMed ID: 17639060
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
    Massironi S, Rossi RE, Casazza G, Conte D, Ciafardini C, Galeazzi M, Peracchi M.
    Neuroendocrinology; 2014 Jun 10; 100(2-3):240-9. PubMed ID: 25428270
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Management of pancreatic neuroendocrine tumors.
    Dabizzi E, Panossian A, Raimondo M.
    Minerva Gastroenterol Dietol; 2010 Dec 10; 56(4):467-79. PubMed ID: 21139544
    [Abstract] [Full Text] [Related]

  • 16. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.
    Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M.
    Ann Surg Oncol; 2010 Sep 10; 17(9):2427-43. PubMed ID: 20217257
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.
    Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, Scherag A, Hahmann M, Müller HH, Barth P.
    Clin Gastroenterol Hepatol; 2008 Jul 10; 6(7):820-7. PubMed ID: 18547872
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.